TrAMPoline Pharma was founded with a vision to support the next generation of cellular immunotherapies to treat solid tumors. We are developing vectors encoding proprietary co-receptor and signaling proteins to improve the performance, safety, and manufacture of all forms of cellular immunotherapy. Our first product, MightyTIL™ (TP-102), is a gene-modified tumor infiltrating lymphocyte therapy which has shown superiority in vitro and in vivo vs. conventional, unmodified, TILs (e.g., Amtagvi™). We have secured over $15M in grant, pre-seed, and philanthropic funding to carry-out a first-in-human trial of MightyTILs to be initiated 1Q 2026. In addition to TP-102, we have expanded our platform to include 3 new products to enhance TIL function, enhance TIL numbers and quality in vivo prior to harvest, and to create a universal TCR-T cell candidate. We are seeking seed-financing for pre-clinical development of our pipeline and to position the company to successfully raise series A financing.